Sensitization and Desensitization in Vascularized Composite Allotransplantation.

dc.contributor.author

Moris, Dimitrios

dc.contributor.author

Cendales, Linda C

dc.date.accessioned

2023-05-01T13:36:40Z

dc.date.available

2023-05-01T13:36:40Z

dc.date.issued

2021-01

dc.date.updated

2023-05-01T13:36:39Z

dc.description.abstract

Vascularized composite allotransplantation (VCA) is a field under research and has emerged as an alternative option for the repair of severe disfiguring defects that result from severe tissue loss in a selected group of patients. Lifelong immunosuppressive therapy, immunosuppression associated complications, and the effects of the host immune response in the graft are major concerns in this type of quality-of-life transplant. The initial management of extensive soft tissue injury can lead to the development of anti-HLA antibodies through injury-related factors, transfusion and cadaveric grafting. The role of antibody-mediated rejection, donor-specific antibody (DSA) formation and graft rejection in the context of VCA still remain poorly understood. The most common antigenic target of preexisting alloantibodies are MHC mismatches, though recognition of ABO incompatible antigens, minor histocompatibility complexes and endothelial cells has also been shown to contribute to rejection. Mechanistically, alloantibody-mediated tissue damage occurs primarily through complement fixation as well as through antibody-dependent cellular toxicity. If DSA exist, activation of complement and coagulation cascades can result in vascular thrombosis and infarction and thus rejection and graft loss. Both preexisting DSA but especially de-novo DSA are currently considered as main contributors to late allograft injury and graft failure. Desensitization protocols are currently being developed for VCA, mainly including removal of alloantibodies whereas treatment of established antibody-mediated rejection is achieved through high dose intravenous immunoglobulins. The long-term efficacy of such therapies in sensitized VCA recipients is currently unknown. The current evidence base for sensitizing events and outcomes in reconstructive transplantation is limited. However, current data show that VCA transplantation has been performed in the setting of HLA-sensitization.

dc.identifier.issn

1664-3224

dc.identifier.issn

1664-3224

dc.identifier.uri

https://hdl.handle.net/10161/27252

dc.language

eng

dc.publisher

Frontiers Media SA

dc.relation.ispartof

Frontiers in immunology

dc.relation.isversionof

10.3389/fimmu.2021.682180

dc.subject

Humans

dc.subject

Isoantibodies

dc.subject

HLA Antigens

dc.subject

Desensitization, Immunologic

dc.subject

Immune Tolerance

dc.subject

Transplantation Immunology

dc.subject

Graft Rejection

dc.subject

Graft Survival

dc.subject

Disease Management

dc.subject

Vascularized Composite Allotransplantation

dc.subject

Immunosuppression Therapy

dc.title

Sensitization and Desensitization in Vascularized Composite Allotransplantation.

dc.type

Journal article

duke.contributor.orcid

Moris, Dimitrios|0000-0002-5276-0699

duke.contributor.orcid

Cendales, Linda C|0000-0002-3461-8824

pubs.begin-page

682180

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Staff

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Orthopaedic Surgery

pubs.organisational-group

Surgery

pubs.organisational-group

Surgery, Plastic, Maxillofacial, and Oral Surgery

pubs.publication-status

Published

pubs.volume

12

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Sensitization and Desensitization in Vascularized Composite Allotransplantation.pdf
Size:
382.35 KB
Format:
Adobe Portable Document Format